Back to Resource Library
Sustained Efficacy of Long-Acting Cabotegravir for PrEP Among Cisgender Women
8 August 2022
This press release provides an overview of the new findings from HPTN 084, a trial of the HIV Prevention Trials Network studying injectable cabotegravir for PrEP among cisgender women. The updated results show reductions in HIV incidence were sustained in the 12 months following unblinding and were presented at the AIDS 2022 conference in Montreal.